Search CDNA
CareDx, Inc.
Nasdaq · CIK 1217234
Last close67.15
Daily change+0.92 (1.39%)
10 Years gain+1690.67%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CDNA · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
76.1Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue14
Quarterly Revenue53
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth12.1 / 25
Quality18.2 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics8.5 / 10
Forward Indicators2.4 / 5
Signals
Operating leverageOperating margin improved by 40.7862 percentage points.
ROIC expansionROIC improved by 93.4639 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 3.3295%.
Key Metrics
Revenue Growth TTM31.48%OK
Revenue CAGR 3Y5.68%OK
Gross Margin100%OK
Operating Margin23.62%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC68.67%OK
Incremental Operating Margin 3Y124.29%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-3.33%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $379.81M | $379.81M | -$30.78M | $42.03M | n/a | 100% | -8.1% | n/a | -19.96% | 53.29M |
| 2025 FY Dec 31, 2024 | $333.79M | $333.79M | $40.77M | $38.05M | n/a | 100% | 12.21% | n/a | 56.41% | 56.62M |
| 2025 FY Dec 31, 2023 | $280.32M | $280.32M | -$203.36M | -$18.39M | n/a | 100% | -72.55% | n/a | -196.24% | 53.76M |
| 2024 FY Dec 31, 2022 | $321.79M | $321.79M | -$77.23M | -$25.24M | n/a | 100% | -24% | n/a | -47.81% | 53.32M |
| 2023 FY Dec 31, 2021 | $296.40M | $296.40M | -$29.73M | -$19.29M | n/a | 100% | -10.03% | n/a | -27.57% | 52.24M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $436.38M | sum latest 4 fiscal quarters Revenue | OK | 0001217234-26-000046, 0001217234-25-000063 |
| Revenue Growth TTM | 31.48% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001217234-26-000046, 0001217234-25-000063 |
| Revenue CAGR 3Y | 5.68% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001217234-26-000018 |
| Revenue CAGR 5Y | 14.59% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001217234-26-000018 |
| Gross Profit CAGR 3Y | 5.68% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001217234-26-000018 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001217234-26-000046, 0001217234-25-000063 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001217234-26-000046, 0001217234-25-000063 |
| Operating Margin | 23.62% | Operating Income / Revenue | OK | 0001217234-26-000046, 0001217234-25-000063 |
| ROIC | 68.67% | NOPAT / Average Invested Capital | OK | 0001217234-26-000046, 0001217234-25-000063 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001217234-26-000046 |
| Current Ratio | 4.58x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $8.17 | Revenue / Diluted Shares | OK | 0001217234-26-000046, 0001217234-25-000063 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |